title: Systemic Treatment in HPV-Induced Recurrent or Metastatic HNSCC.
abstract: Recurrent or metastatic head and neck cancer describes tumor deposits that arise locally, regionally, or at distant sites after treatment or distant metastases at the time of primary diagnosis. Prognosis for R/M squamous cell carcinomas of the head and neck (HNSCC) is poor and treatment options are limited in this situation. Human papillomavirus (HPV) is an important risk factor for HNSCC. About 40 % of all HNSCC have been attributed to HPV in Europe. HPV positivity at initial diagnosis is the single best prognostic factor for survival. However, data for the prognostic and predictive value of HPV in the R/M situation are still scarce. Due to the rising incidence of HPV-associated cancers, the number of R/M HPV+ carcinomas is also expected to rise. This chapter therefore aims to give an overview of the current knowledge concerning the role of HPV as a prognostic and predictive marker in recurrent or metastatic HNSCC.
authors.affiliation: Charité Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Berlin, Germany.
authors.forename: Damian T
authors.initials: DT
authors.lastname: Rieke
authors.affiliation: Charité Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Berlin, Germany. ulrich.keilholz@charite.de.
authors.forename: Ulrich
authors.initials: U
authors.lastname: Keilholz
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism; D002294:Carcinoma, Squamous Cell / Q000378:metabolism / Q000628:therapy* / Q000821:virology; D006258:Head and Neck Neoplasms / Q000378:metabolism / Q000628:therapy* / Q000821:virology; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000378:metabolism / Q000628:therapy* / Q000821:virology; D027383:Papillomaviridae / Q000472:pathogenicity; D030361:Papillomavirus Infections / Q000378:metabolism / Q000628:therapy* / Q000821:virology; D000077195:Squamous Cell Carcinoma of Head and Neck
chemical_list: D014408:Biomarkers, Tumor
keywords: Checkpoint inhibitor; Chemotherapy; EGFR inhibitor; HPV; Predictive biomarker; R/M HNSCC; Targeted therapy